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Abstract
Background: Leishmania infantum is a protozoan parasite transmitted by phlebotomine sand flies that causes
life-threatening disease in humans and dogs. The dog is the primary reservoir of the parasite and early diagnosis
of canine leishmaniosis is crucial at the clinical and epidemiological level. The currently available serological tests
for CanL diagnostic show limitations therefore the aim of the present study was to investigate the diagnostic
performance of an indirect antibody ELISA based on the Leishmania infantum recombinant antigen PFR1 in
asymptomatically infected dogs. One hundred fifty-six dogs including Leishmania-free experimental Beagles and
pet dogs from England, Scotland and Leishmania-endemic Murcia in Spain, were tested with the assay. The later
were also tested with two commercial L. infantum crude antigen ELISAs (INgezim and Civtest, respectively) and
a real-time kinetoplast PCR test.
Results: Anti-PFR1 antibodies were detected in the four groups of dogs, and the mean log-transformed optical
density (OD) values were lowest in Beagles and in dogs from England and highest among dogs from Murcia
(p < 0.05). Using the highest OD in beagles as the PFR1 ELISA cut-off point, the estimated seroprevalence was
27% (14-40%) in dogs from Murcia, 4% (0-9%) in dogs from Scotland and 3% (0-8%) in dogs from England
(p < 0.05). Seroprevalence in dogs from Murcia according to the INgezim and Civtest ELISAs were 24% (12-37%)
and 31% (18-45%), respectively, whilst the prevalence of infection based on PCR in these dogs was 73% (60-86).
The percentages of PFR1-positive dogs that tested negative on the INgezim and Civtest ELISAs were 30% and
35%, respectively, and all of them tested positive on the PCR test. Relative to the PCR, the specificity, sensitivity
and area under the ROC curve of the PFR1 ELISA were 100%, 36% and 0.74 (0.63-0.86), respectively.
Conclusions: The ability shown by the PFR1 ELISA to detect infected dogs that go undetected by the crude antigen
ELISAs is clinically and epidemiologically useful and PFR1 could be considered a candidate for a multi-antigen-based
immunoassay for early detection of L. infantum infected dogs.
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Background
Leishmania infantum (L. infantum) transmitted by phle-
botomine sand flies, infects reticuloendothelial cells
causing potentially life-threatening human and canine
leishmaniosis (CanL). Since the advent of PCR diagnosis,
it has been found that 50-80% of dogs endemic to areas
such as the Murcia Region in Southeast Spain are
chronically infected and that most remain asymptom-
atic [1]. The development of the disease is strongly
influenced by the host’s immunity, which tends to be
polarized towards either a Th1 cell- or a Th2
antibody-mediated response [2, 3]. The latter is com-
monly associated with disease susceptibility resulting
from the widespread deposition of antibody-antigen
complexes in capillaries. Subclinically infected dogs,
particularly those in preclinical stages, may transmit
infection to sand flies [4, 5]. Consequently, serological
diagnosis of Leishmania infection is clinically and epi-
demiologically useful.
The estimated seroprevalence of CanL in endemic
areas is typically 10-30% depending on the dog’s habitat
and exposure to infection as well as on the sensitivity
(Se) and specificity (Sp) of the diagnostic test. Se and Sp
vary according to the antigens used - crude, soluble,
purified or recombinant antigens - and the immuno-
logical method used for detection. The most common
types of immunoassay used for epidemiological and
surveillance purposes are indirect immunofluorescence
assays (IFAs), enzyme-linked immunosorbent assays
(ELISAs), and rapid immunochromatographic tests
(ICTs) [6, 7]. The IFA is considered the reference test.
However, its Se may range from 60% to 100% [8, 9],
and it is known that false positives may arise from
cross-reactivity with other protozoan and bacterial in-
fections [7, 10, 11]. The antigens used in these types of
tests might be either crude antigens obtained from cul-
tures of the parasite or recombinant antigens expressed
in heterologous expression systems. The tests based on
recombinant antigens are more specific and easier to pro-
duce and standardize and have been used for Leishmania
spp. serodiagnosis in human and dogs [12–15]. Among
the antigens composing these tests, rK39, a repetitive,
conserved, protein in Leishmania donovani complex spe-
cies [16], has been widely used. The validity of tests based
on rK39 depends on time since infection and presence of
active disease. In a recent meta-analysis study, the overall
Se of rK39-based ICT tests in infected asymptomatic dogs
was only 50% [17]. The authors suggested that using a
combination of recombinant antigens should improve
test Se. The advantage of this approach in the sero-
logical diagnosis of L. infantum infection in dogs was
later shown [14].
In the search for vaccine candidates, a highly im-
munogenic protein from L. infantum named PFR1
was cloned and expressed as recombinant protein.
PFRs, or paraflagellar rod proteins, represent a family
of relevant trypanosomatid antigens located in the
paraflagellar pocket of these parasites [18–20]. Knock-
out assays in Leishmania mexicana evidenced that
the proteins encoded by PFR genes play a critical role
in the mobility and survival of the parasite [21]. Some
members of the PFR antigen family stand out for
their high immunogenicity [22]. The sera from both
asymptomatic and cardiac Chagas’ disease patients
showed a higher level of antibodies against PFR anti-
gens of Trypanosoma cruzi (T. cruzi) than sera from
healthy donors [23].
Given the limitations of presently available serological
tests for CanL and the high immunogenicity of PFR an-
tigens, the present article evaluated the seroreactivity of
dogs to the PFR1 recombinant protein and the validity
of a PFR1-based ELISA for the diagnosis of asymp-
tomatic CanL.
Methods
Cloning of PFR1 coding sequence in pQE32 expression
vector; overexpression and purification of the PFR1
recombinant antigen
The PFR1 coding sequence was amplified by PCR using
L. infantum genomic DNA as a template along with the
primers PFR1Li-ATG (5’GAATGGATCCCCCCTGAAGA
TGCG3’) and PFR1Li-TAAKpn1 (5’GTAAGGTACCC
CTCCAGCTGCGTGCTCG3’), which bear BamHI and
KpnI restriction sites, respectively. The 1775 bp amplified
fragment was cloned into a pGEM-T Easy vector
(Promega®) and sequenced. The PFR1 gene was subse-
quently excised from the pGEM-T-PFR1 clone by BamHI
and Asp718 digestion and in-frame cloned into the
Escherichia coli (E. coli) pQE32 expression vector digested
with the same enzymes. The resulting clone was se-
quenced and named pQE-32 PFR1Li.
The recombinant PFR1 protein was overexpressed by
adding 0.02 mM of isopropyl-beta-D-thiogalactopyranoside
(IPTG) to the E. coli M15 strain transformed with pQE-
32-PFR1Li and grown for 3 h at 37 °C. Total proteins
were solubilized in solubilization buffer (0.3 M NaCl,
50 mM NaH2PO4, 1 mM phenyl methyl sulfonyl fluor-
ide, pH 8.0) and by sonication. Recombinant PFR1 was
subsequently purified to homogeneity under native
conditions by Ni2+-NTA affinity chromatography to a
6× histidine tag placed at the NH2-terminus of PFR1.
After washing, the protein was eluted in solubilization
buffer at pH 6.0. The final elution fraction resulting
from the purification process was analysed in triplicate
by 10% SDS-PAGE and Coomassie Blue staining (Fig. 1).
The protein concentration was measured with a Micro
BCA Protein Assay Kit (Thermo).
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Western blot analysis
Purified PFR1 recombinant protein was electrophoresed
in a 10% SDS-PAGE and transferred to PVDF mem-
branes (Immobilon-P) by following standard procedures
as previously described [24]. Western blotting was per-
formed in duplicate according to standard techniques.
For PFR1 detection, an antibody raised against the PFR2
protein of T. cruzi was used as primary antibody [20] at
1:2000 dilution. The secondary antibody was an HRP-
conjugated anti-rabbit IgG (Sigma) at 1:20,000 dilution.
The blots were subjected to peroxidase and luminol/
enhancer solutions using a SuperSignal® West Pico
Chemiluminescent Reagent Kit (Thermo Scientific),
and subsequently exposed to Kodak X-Omat auto-
radiographic film.
Study population and design
The study was performed using samples from 156 dogs
(58% males and 42% females), including 70 dogs from
Murcia participating in Leishmania research projects at
the University of Murcia and 86 dogs from the United
Kingdom undergoing veterinary care for problems unre-
lated to Leishmania infection. Murcia samples came
from two groups of dogs: 25 beagles and 45 mixed-breed
dogs aged between 6 months and 15 years old (Beagles;
mean 1 year and 6 months. Mixed-breed Murcia group;
mean 3 years and 7 months). Similarly, samples from UK
dogs were from 50 dogs aged between 3 months and-
15 years old (mean 7 years and 4 months) coming from
Scotland and 36 dogs aged between 4 months and 13 years
old (mean 6 years and 8 months) coming from South
West England. All dogs from the UK were cross-breed.
The beagles had been recently bought from an autho-
rized breeder (Isoquimen SL., Barcelona, Spain) for a L.
infantum vaccination trial, who selected the dogs based
on age and gender balance. They were used as a
Leishmania-negative control group after their status was
confirmed by an IFAT serological test performed by the
breeder and a real-time Leishmania kinetoplast-specific
PCR (kPCR) using DNA from bone marrow samples as
a template (described below). The Murcia group of dogs
were a random selection of mostly abandoned animals
living in peri-urban areas of the city of Murcia, a typic-
ally L. infantum endemic area [25], rescued and eutha-
nized by the local authority as part of a municipal
zoonosis control program. Serum and tissue (spleen,
lymph node and skin) samples taken immediately after
death were similarly tested for L. infantum antibodies
using two commercial ELISA tests (described below)
and the kPCR, respectively. The UK dogs were pet ani-
mals and samples used was surplus serum taken for
other diagnostic tests. Hence, they were not tested for L.
infantum DNA and were only analysed for L. infantum
antibodies with the PFR1 ELISA assay developed in this
work (described below). The UK is a Leishmania-free
country. However, the travel history of the UK dogs in-
corporated in this study was unknown. We cannot rule
out that some of the UK dogs had been in Leishmania-
endemic Southern Europe and exposed to Leishmania
infection.
Detection of specific anti-PFR1 antibodies by ELISA
Serum from all dogs, obtained from blood samples col-
lected from the cephalic vein into vacuum tubes, was
tested for anti-PFR1 antibodies by ELISA. ELISAs were
performed in triplicate at different dilutions by following
previously described procedures [26]. Positive and nega-
tive control sera were included in all plates. Briefly,
ELISA 8-well strips (Nunc-Immuno module F16; Ros-
kilde, Denmark) were coated with 0.5 μg/well of PFR1 in
a carbonate buffer. After being coated, the plates were
stored in a dry atmosphere at −20 °C until use. The wells
were washed twice with 200 μL of PBS-0.05% TWEEN
20 and blocked by incubation for 90 min with 5% non-
fat dried milk powder in PBS (blocking solution) at 37 °C.
Subsequently, canine sera at 1/100 and 1/200 dilutions in
blocking solution were added to the dry blocked wells and
incubated for 2 h at 37 °C. Before the secondary antibody
Fig. 1 Expression and purification of L. infantum recombinant PFR1
protein. a Analysis by SDS-PAGE and Coomassie blue staining of the
protein purification process. The Escherichia coli M15 strain was chosen
as the host bacterium for LiPFR1 overexpression (lane 1). An intense
band of approximately 70 kDa was observed after IPTG induction
(lane 2) and not seen in uninduced cultures (lane 1). Purified LiPFR1
protein after purification by Ni2+ affinity chromatography is shown in
lane 3. MW, molecular weight marker (kDa). b Western blot analysis of
L. infantum PFR1 recombinant protein by using α-PFR2 antibody
against the homologous PFR2 protein from T. cruzi. MW, molecular
weight marker (kDa)
Ledesma et al. BMC Veterinary Research  (2017) 13:304 Page 3 of 8
was added, the plates were washed five times with 200 μL
of PBS-0.05% TWEEN 20 and incubated for 1 h with
peroxidase-conjugated anti-dog IgG (Sigma) in blocking
solution at a 1/10000 dilution at 37 °C. After incubation,
the plates were washed five times with 200 μL of PBS-
0.05% TWEEN 20, and the reaction was developed using
ortho-phenylenediamine and hydrogen peroxide in a
citrate buffer for 5 min in the dark at room temperature.
Finally, 8 N sulfuric acid was used to stop the reaction,
and the absorbance was measured at 492 nm.
Commercial L. infantum antibody ELISAs
Commercial antibody tests to detect serum L. infantum
IgG included INgezim Leishmania® (Ingenasa, Spain)
and Civtest Canis Leishmania® (Hipra, Spain, later com-
mercialized by Esteve, Spain as Leiscan®). Both tests use
crude immunodominant L. infantum antigens for cap-
turing specific IgGs. For detection, the INgezim test uses
conjugation to a specific canine IgG monoclonal anti-
body, whilst Civtest uses a generic protein A/HRPO con-
jugate. The validity of these tests has been assessed by
the manufacturers using IFA as the reference test. The
INgezim results showed 95% and 80% agreement for
1/100 and 1/160 IFA cut-offs, respectively, whilst the
estimated sensitivity (Se) and specificity (Sp) of the
Civtest assay were 98% and 96%, respectively. More-
over, the performance of both tests was recently
assessed on experimentally infected dogs [27], and Sp
was 100% for both tests whilst Se was 98% for Civtest
and 78% for INgezim.
Samples were done in duplicate, and antibody optical
densities (OD) were read in a spectrophotometer. The
mean of the two readings was used to classify samples as
positive, negative, or inconclusive by following the man-
ufacturers’ instructions.
L. infantum-specific real-time PCR
Tissue samples from dogs of the Murcia group were
stored at −20 °C until used for DNA purification using a
nucleic acid purification robot (Maxwell® 16, Promega).
Bone-marrow samples of Beagles were obtained by nee-
dle aspiration, mixed with a protein digestion solution
(10 mM Tris-HCl, 10 mM NaCl, 10 mM EDTA, pH = 8;
0.1 mg/ml of proteinase K and 1% of SDS) and the DNA
was extracted within 48 h with DNeasy Blood and tissue
kit, Quiagen.. The DNA was analysed for L. infantum
kinetoplast sequences using a TaqMan probe in a real-
time PCR [28, 29]. The analyses were done in duplicate
using 300 ng of high-quality template DNA (A260/
A280 ≥ 1.7) per PCR reaction. Samples from dogs with
clinical leishmaniosis and uninfected dogs were used as
positive and negative amplification controls, respectively.
A semi-quantitative measure of parasite DNA load was
obtained by estimating the PCR amplification threshold
cycle (CT) at which near-logarithmic PCR product gen-
eration was detected [30]. Samples with CT = 1-38 were
considered positive.
Statistical analysis
Analyses were carried out in R (http://www.R-project.org).
Anti-PFR1 antibody OD distributions were analysed and
normalized using a decimal logarithmic transformation of
ODx100 (LOD). The mean LODs between levels of ex-
planatory variables, including dog origin, gender and age
(categorized as ≤1 yrs., 2 yrs., 3 yrs. and ≥4 yrs), were com-
pared using ANOVA. A multivariable linear regression
model was then used to investigate the independent con-
tributions of explanatory variables to LOD in dogs of the
Murcia group [31].
A LOD cut-off value was selected to classify dogs as
seronegative or seropositive by adding one decimal to
the largest OD among the Leishmania-negative Beagle
dogs. Differences in the proportion of seropositive dogs
across levels of explanatory variables were analysed
using the chi-squared test or with Fisher’s exact test
when one of the expected values in the contingency
table was less than five [32].
A logistic regression model was developed to analyse
the multivariable relationship between the serological
status of the Murcia dogs and their age and gender.
Receiver operating characteristic (ROC) curves [33] were
used to evaluate the performance of the test and calculate
Se, Sp with respect to the PCR test in skin and lymphoid
tissue samples, considered the reference test [34].
Cohen’s kappa coefficient [32] was employed to
evaluate the degree of agreement between the results
of qualitative tests by following the scale: 0, no agree-
ment; >0- < 0.2, slight; 0.2- < 0.4, fair; 0.4- < 0.6, moder-
ate; 0.6- < 0.8, substantial; and >0.8, almost perfect.
A 5% (p < 0.05) significance level for a two-tailed test
was considered in all comparisons.
Results
Purification of Leishmania infantum recombinant PFR1
protein
Figure 1a shows the analysis by SDS-PAGE of the PFR1
recombinant protein purified as described in Materials
and Methods. An intensely stained band with the ex-
pected electrophoretic mobility of approximately 70 kDa
was observed (Fig. 1a, lane 3). The purity was >95% as
assessed by band densitometry analysis after Coomassie
blue staining.
The 70 kDa band was the only one detected by the
antibody used in the Western blot (Fig. 1b), therefore in-
dicating the integrity of the purified PFR1 protein. In
addition, the purified protein was tested with the E-
Toxate reaction kit (Sigma), which showed it to be free
from bacterial LPS contaminants.
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Antibody optical density distribution for PFR1 ELISA
The mean and median (range) LOD values obtained in the
PFR1 ELISA were 0.705 and 0.680 (0.014-1.760), respect-
ively, and differed significantly according to the dogs’ origin
(Table 1). Median LODs were lower for beagles and dogs
from England than for the Murcia dogs (p < 0.05). The
remaining differences in median LOD between groups
were not statistically significant (p < 0.05) (Table 1).
Within the Murcia group, LOD was positively associated
with age and the median LOD was greater in females than
in males (Table 1). The multivariable linear regression
model confirmed the independent association of both age
and gender with LOD (results not tabulated) (p < 0.05).
Estimated seroprevalence based on the PFR1 and
commercial ELISAs. Prevalence based on PCR and
diagnostic performance of the PFR1 ELISA
Considering a cut-off LOD of 1.080 - a value one
thousandth of a unit higher than the highest LOD in the
beagles (Table 1) - PFR1 seroprevalence (95% CI) was
27% (14-40) in dogs from Murcia, 4% (0-9) in dogs from
Scotland and 3% (0-8) in dogs from England (p < 0.05)
(Table 2).
The estimated seroprevalence in dogs from Murcia,
according to the INgezim and Civtest ELISAs, was 24%
(12-37) and 31% (18-45), respectively. The prevalence of
asymptomatic infection assessed by PCR in these dogs
was 73% (60-86) (Table 2).
In logistic regression models including gender and age,
the probability of being seropositive in dogs from Murcia
was not significantly associated to either variable.
Relative to the PCR test, which was performed only in
the beagles and Murcia dogs, the PFR1 ELISA Sp and Se
at a cut-off of 1.080 were 100% and 36%, respectively.
The AUC (95% CI) was 0.74 (0.63-0.86).
Diagnostic agreement between tests
The levels of agreement between the different diagnostic
tests performed in dogs from Murcia are shown in
Table 3. The kappa coefficient from comparing the PFR1
Table 1 PFR1 normalized optical density according to origin, age and gender
Variable Level N° dogs Mean Percentiles
0% 10% 25% 50% 75% 90% 100%
Origin Beagles 25 0.651 0.067 0.241 0.335 0.490 0.673 0.899 1.079
Murcia 45 0.706 0.247 0.563 0.653 0.746 1.160 1.245 1.760
England 36 0.844 0.014 0.301 0.546 0.645 0.720 1.021 1.346
Scotland 50 0.532 0.091 0.322 0.443 0.734 0.957 1.057 1.509
All 156 0.705 0.014 0.319 0.510 0.680 0.892 1.076 1.760
Age (years)a ≤1 8 0.686 0.247 0.280 0.488 0.655 0.824 1.190 1.193
2 15 0.757 0.426 0.500 0.625 0.746 0.814 1.066 1.239
3 8 0.800 0.580 0.663 0.712 0.731 0.792 1.031 1.272
4 12 1.057 0.630 0.644 0.740 1.020 1.256 1.559 1.760
Gendera Male 24 0.772 0.426 0.560 0.638 0.716 0.856 1.203 1.249
Female 19 0.978 0.294 0.634 0.724 0.845 1.216 1.340 1.760
aDogs from Murcia only
Table 2 Estimated PFR1, Ingezym and Civtest ELISA seroprevalence according to dog origin, age and gender
Variable Level N° dogs PFR1 Ingezym Civtest PCR
Origen Murcia 45 27 (14–40) 24 (12–37) 31 (18–45) 73 (60–86)
Beagles 25 0 (0–0) – – 0 (0–0)
Scotland 50 4 (0–9) – – –
England 36 3 (0–8) – – –
Age (years)a ≤1 8 25 (0–55) 0 (0–0) 13 (0–35) 75 (45–100)
2 15 13 (0–31) 27 (4–49) 40 (15–65) 93 (81–100)
3 8 13 (0–35) 38 (4–71) 25 (0–55) 50 (15–85)
≥4 12 50 (22–78) 25 (1–50) 33 (7–60) 67 (40–93)
Gendera Male 24 17 (2–32) 21 (5–37) 25 (8–42) 71 (53–89)
Female 19 42 (20–64) 32 (11–52) 42 (20–64) 79 (61–97)
aDogs from Murcia only
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ELISA with other serological techniques ranged from
0.23 to 0.36 (fair agreement), while the result of com-
paring the commercial ELISAs INgezim and Civtest
was 0.61 (substantial agreement). Comparing the sero-
logical tests with the PCR test, the kappa coefficient
ranged from 0.14 (slight agreement) for INgezim to
0.28 (fair agreement) for Civtest (Table 3).
Table 4 shows the percentage of discordant samples
tested with two serological tests (T1 and T2) and the
percentage of these samples that were PCR positive. The
percentage of PFR1 ELISA positives that were negative
to the INgezim and Civtest ELISAs were 35% and 30%,
respectively, and all these samples were PCR positive.
On the other hand, the percentage of samples that
tested negative on the PFR1 ELISA and positive on the
INgezim and Civtest ELISAs were 29% and 40%, re-
spectively, and whilst all of the latter (Civtest ELISAs)
were PCR positive, only 80% of the former (INgezim)
were PCR positive (Table 4).
Discussion
The results obtained in the present study are consistent
with PFR1 stimulating a specific antibody response in
dogs asymptomatically infected with L. infantum. One-
third of all seropositive dogs were only detected with the
PFR1 ELISA and not by the commercial ELISAs. Con-
versely, the PFR1 ELISA failed to detect another third of
seropositive dogs according to the commercial ELISAs. To-
gether, these results suggest that the PFR1 antigen might be
a useful candidate to incorporate in a multi-antigen ELISA
for serological detection of asymptomatically infected dogs.
To further explore this use, cross-reactivity between PFR1
and other recombinant antigens used for Leishmania infec-
tion diagnosis such as the rK39 antigen should be analysed.
Although the UK is a Leishmania-free zone, 3-4% of
the UK dogs included in this study tested positive to the
PFR1 ELISA. This result might indicate that some PFR1
conformational epitopes are shared with proteins present
in other pathogens or that the seropositive UK dogs
were actually infected with L. infantum. The latter can-
not be ruled out since the travel history of the UK dogs
was unknown and no samples were available for PCR
testing. Serological cross-reaction has been reported
between Leishmania antigens and antigens of other
pathogens present in the UK such as Ehrlichia canis,
Babesia canis, Anaplasma phagocytophilum, Rickettsia
conori, Toxoplasma gondii, Neospora caninum and
Hepatozoon canis [7, 10, 11, 35]. However, arguing against
cross-reactivity, at the selected cut-off LOD of 1.080, the
specificity of the PFR1 ELISA relative to the PCR test
performed only in beagles and dogs from Murcia was
100%. In comparison, the homologous PFR2 protein from
T. cruzi is recognized by the sera from asymptomatic cha-
gasic patients with a specificity and sensitivity of 92% and
75%, respectively. It is worth mentioning that the sera
from patients with leishmaniasis also recognize this
protein.
The sensitivity of the PFR1 ELISA compared to the
PCR test was 36%, similar to that estimated for commer-
cial ELISAs. This low sensitivity value might be expected
when analysing asymptomatically infected dogs since
most dogs develop a predominantly cellular immune
Table 3 Kappa coefficient and degree of agreement between PFR1, INgezim (Ing) and Civtest (Civ) ELISA tests
Techniques N° dogs PFR1 Ing Civ Ing + Civ PCR
PFR1 45 – Fair Fair Fair Fair
Ing 45 0.36 (0.05–0.67) – Substantial Substantial Slight
Civ 45 0.24 (0.00–0.55) 0.61 (0.36–0.87) – Almost perfect Fair
Ing + Civ 45 0.28 (0.00–0.57) 0.74 (0.53–0.95) 0.90 (0.77–1.00)
PCR 45 0.23 (0.08–0.39) 0.14 (0.00–0.29) 0.28 (0.11–0.45) 0.26 (0.06–0.45) –
Table 4 Percentage of positives to one of two ELISA techniques (T1 and T2) including PFR1, INgezim (Ing) and Civtest (Civ) ELISA
tests, and their PCR status
Techniques T1+; T2- T1-; T2+
T1 T2 % Seropositive % PCR positive % Seropositive % PCR positive
PFR1 Ing 30 100 29 80
PFR1 Civ 35 100 40 100
PFR1 Ing + Civ 24 100 43 100
Ing Civ 14 50 31 100
Ing Ing + Civ 0 – 31 100
Civ Ing + Civ 0 – 13 50
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response to the parasite while the humoural response
might be variable and in some cases undetectable by
these tests [34]. The reason why the PFR1 ELISA identi-
fied specific antibodies that were not detected by the
commercial tests based on crude immunodominant anti-
gens is unclear. In crude antigen extract preparations,
specific epitopes might not be available for binding spe-
cific antibodies.
PFR1 ELISA LODs and seroprevalence were greater
in older dogs and LODs in females compared to
males. Given the small number of dogs from Murcia,
the accuracy of age and gender-specific estimates in
this study was limited. There is no previous evidence
of gender-specific susceptibility to leishmaniasis, but
increasing seroprevalence during the first years of life
is typical and is associated with accumulated exposure
to infection [36]. Age- and sex-specific differences be-
tween studies depend on the degree to which dogs
are naturally exposed to Leishmania infection, which
is greatest for dogs living outdoors in peri-urban and
rural areas and not receiving preventive insecticidal
treatments [25].
In summary, the present study highlights the potential
of PFR1 recombinant antigen for L. infantum serological
diagnoses. Further studies need to be carried out to in-
vestigate the test specificity and its performance when
combined with other relevant recombinant antigens for
diagnostics of CanL.
Conclusions
PFR1 recombinant antigen detects specific antibody
responses in L. infantum-infected dogs and could be a
useful antigen to incorporate in a multi-antigen im-
munoassay to detect asymptomatically infected dogs.
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